Table 1 Clinical characteristics of patients accepted ICI therapy
Characteristic | Non-HPD | HPD | p value | Method |
|---|---|---|---|---|
N | 831 | 36 | Â | Â |
Gender, N (%) | Â | Â | 0.032 | Chisq.test |
 Female | 222 (26.71%) | 16 (1.93%) |  |  |
 Male | 609 (73.29%) | 20 (2.41%) |  |  |
Pathology Type, N (%) | Â | Â | 0.008 | Chisq.test |
 Adenocarcinoma | 411 (49.46%) | 18 (2.17%) |  |  |
 Sarcoma | 10 (1.2%) | 3 (0.36%) |  |  |
 Small Cell Carcinoma | 145 (17.45%) | 4 (0.48%) |  |  |
 Squamous | 188 (22.62%) | 6 (0.72%) |  |  |
 Others | 77 (9.27%) | 5 (0.6%) |  |  |
Differentiation, N (%) | Â | Â | 0.349 | Chisq.test |
 Low Differentiation | 442 (53.19%) | 14 (1.68%) |  |  |
 Low To Median Differentiation | 78 (9.39%) | 5 (0.6%) |  |  |
 Median Differentiation | 131 (15.76%) | 7 (0.84%) |  |  |
 Median To High Differentiation | 14 (1.68%) | 2 (0.24%) |  |  |
 High Differentiation | 6 (0.72%) | 0 (0) |  |  |
 Unknown | 160 (19.25%) | 8 (0.96%) |  |  |
Ki-67, N (%) | Â | Â | 0.989 | Chisq.test |
 0–25% | 51 (6.14%) | 2 (0.24%) |  |  |
 26–50% | 71 (8.54%) | 4 (0.48%) |  |  |
 51–75% | 91 (10.95%) | 4 (0.48%) |  |  |
 76–100% | 93 (11.19%) | 4 (0.48%) |  |  |
 Unknown | 525 (63.18%) | 22 (2.65%) |  |  |
TNM Stage, N (%) | Â | Â | 0.264 | Chisq.test |
 III | 76 (9.15%) | 0 (0) |  |  |
 IV | 725 (87.24%) | 36 (4.33%) |  |  |
 Unknown | 22 (2.65%) | 0 (0) |  |  |
Smoking, N (%) | Â | Â | 0.589 | Fisher.test |
 Current | 146 (17.57%) | 8 (0.96%) |  |  |
 Ever | 288 (34.66%) | 10 (1.2%) |  |  |
 Never | 381 (45.85%) | 17 (2.05%) |  |  |
 Unknown | 16 (1.93%) | 1 (0.12%) |  |  |
Drinking, N (%) | Â | Â | 0.702 | Fisher.test |
 Current | 202 (24.31%) | 10 (1.2%) |  |  |
 Ever | 155 (18.65%) | 5 (0.6%) |  |  |
 Never | 459 (55.23%) | 20 (2.41%) |  |  |
 Unknown | 15 (1.81%) | 1 (0.12%) |  |  |
Family History of Tumor, N (%) | Â | Â | 0.525 | Chisq.test |
 Yes | 226 (27.2%) | 8 (0.96%) |  |  |
 No | 456 (54.87%) | 19 (2.29%) |  |  |
 Unknown | 149 (17.93%) | 9 (1.08%) |  |  |
KPS score, N (%) | Â | Â | 0.256 | Chisq.test |
 10–20 point | 30 (3.61%) | 2 (0.24%) |  |  |
 30–40 point | 5 (0.6%) | 0 (0) |  |  |
 70–80 point | 125 (15.04%) | 10 (1.2%) |  |  |
 90–100 point | 661 (79.54%) | 24 (2.89%) |  |  |
 Unknown | 10 (1.2%) | 0 (0) |  |  |
Combined Chemotherapy, N (%) | Â | Â | 0.001 | Chisq.test |
 No | 343 (41.28%) | 25 (3.01%) |  |  |
 Yes | 488 (58.72%) | 11 (1.32%) |  |  |
Combined Antiangio, N (%) | Â | Â | 0.005 | Chisq.test |
 No | 594 (71.48%) | 34 (4.09%) |  |  |
 Yes | 237 (28.52%) | 2 (0.24%) |  |  |
Combined Target Therapy,N (%) | Â | Â | 1.000 | Fisher.test |
 No | 794 (95.55%) | 35 (4.21%) |  |  |
 Yes | 37 (4.45%) | 1 (0.12%) |  |  |
Combined Radiotherapy, N (%) | Â | Â | 0.421 | Fisher.test |
 No | 790 (95.07%) | 33 (3.97%) |  |  |
 Yes | 41 (4.93%) | 3 (0.36%) |  |  |
Combined Other Therapy, N (%) |  |  |  < 0.001 | Chisq.test |
 No | 241 (29%) | 22 (2.65%) |  |  |
 Yes | 590 (71%) | 14 (1.68%) |  |  |
Count of Metastasis Lesion, N (%) | Â | Â | 0.386 | Chisq.test |
 0 | 62 (7.46%) | 1 (0.12%) |  |  |
 1 | 77 (9.27%) | 4 (0.48%) |  |  |
 2 | 71 (8.54%) | 2 (0.24%) |  |  |
 3 | 72 (8.66%) | 1 (0.12%) |  |  |
 4 | 57 (6.86%) | 1 (0.12%) |  |  |
 More than 4 | 492 (59.21%) | 27 (3.25%) |  |  |
Lung Metastasis, N (%) | Â | Â | 0.645 | Chisq.test |
 No | 371 (44.65%) | 18 (2.17%) |  |  |
 Yes | 460 (55.35%) | 18 (2.17%) |  |  |
Brain Metastasis, N (%) | Â | Â | 0.061 | Chisq.test |
 No | 701 (84.36%) | 35 (4.21%) |  |  |
 Yes | 130 (15.64%) | 1 (0.12%) |  |  |
Bone Metastasis, N (%) | Â | Â | 0.959 | Chisq.test |
 No | 608 (73.16%) | 27 (3.25%) |  |  |
 Yes | 223 (26.84%) | 9 (1.08%) |  |  |
Adrenal Metastasis, N (%) | Â | Â | 0.096 | Fisher.test |
 No | 745 (89.65%) | 29 (3.49%) |  |  |
 Yes | 86 (10.35%) | 7 (0.84%) |  |  |
Subcutaneous Metastasis, N (%) | Â | Â | 0.098 | Fisher.test |
 No | 820 (98.68%) | 34 (4.09%) |  |  |
 Yes | 11 (1.32%) | 2 (0.24%) |  |  |
Muscle Metastasis, N (%) | Â | Â | 0.473 | Fisher.test |
 No | 817 (98.32%) | 35 (4.21%) |  |  |
 Yes | 14 (1.68%) | 1 (0.12%) |  |  |
Meningeal Metastasis, N (%) | Â | Â | 1.000 | Fisher.test |
 No | 830 (99.88%) | 36 (4.33%) |  |  |
 Yes | 1 (0.12%) | 0 (0) |  |  |
Pericardial Metastasis, N (%) | Â | Â | 1.000 | Fisher.test |
 No | 811 (97.59%) | 36 (4.33%) |  |  |
 Yes | 20 (2.41%) | 0 (0) |  |  |
Intraabdominal Metastasis, N (%) | Â | Â | 0.111 | Fisher.test |
 No | 729 (87.73%) | 35 (4.21%) |  |  |
 Yes | 102 (12.27%) | 1 (0.12%) |  |  |
Pancreatic Metastasis, N (%) |  |  |  < 0.001 | Fisher.test |
 No | 813 (97.83%) | 29 (3.49%) |  |  |
 Yes | 18 (2.17%) | 7 (0.84%) |  |  |
Liver Metastasis, N (%) | Â | Â | 0.128 | Chisq.test |
 No | 615 (74.01%) | 22 (2.65%) |  |  |
 Yes | 216 (25.99%) | 14 (1.68%) |  |  |
Non-draining Areas Metastasis, N (%) |  |  |  < 0.001 | Fisher.test |
 No | 747 (89.89%) | 22 (2.65%) |  |  |
 Yes | 84 (10.11%) | 14 (1.68%) |  |  |
Pleural Metastasis, N (%) | Â | Â | 0.243 | Fisher.test |
 No | 751 (90.37%) | 35 (4.21%) |  |  |
 Yes | 80 (9.63%) | 1 (0.12%) |  |  |
 Age, Median (IQR) |  |  | 0.303 | Wilcoxon |
 Height, Median (IQR) |  |  | 0.221 | Wilcoxon |
 Weight, Median (IQR) |  |  |  < 0.001 | Wilcoxon |
 BMI, Median (IQR) |  |  |  < 0.001 | Wilcoxon |
 Cycles of Immunotherapy, Median (IQR) |  |  |  < 0.001 | Wilcoxon |